Comment on: Inhibition of EZH2 ameliorates lupus-like disease in MRL/lpr mice.
Systemic lupus erythematosus (SLE) is systemic autoimmune disorder characterized by a range of manifestations such as damage of kidney, bone, skin and impaired immune system regulation. Accumulative evidence showed that genetic factors, environment dysregulation led to imbalanced autoimmunity, contributing to SLE pathogenesis (1). Histone methyltransferase Enhancer of Zeste homolog 2 (EZH2) is a catalytic subunit of Polycomb Repressive Complex 2, and is able to catalyze tri-methylation of histone H3 at lysine 27 to silence its target genes (2).